Humanwell Healthcare gets dapoxetine approval, inks financial services deal

Humanwell Healthcare Group announced that its subsidiary, Wuhan Jiulong Humanwell Pharmaceutical Co., Ltd., received drug registration certificates for dapoxetine hydrochloride tablets (30mg and 60mg) from the National Medical Products Administration. This approval, valid until September 29, 2030, allows Jiulong Humanwell to market the drug for male premature ejaculation, further diversifying Humanwell Healthcare's product portfolio. The company invested approximately 1,000 million yuan in research and development for this drug and will outsource production to Chongqing Boteng Pharmaceutical Co., Ltd.

The dapoxetine hydrochloride tablets market recorded approximately 11 billion yuan in sales across various channels in 2024. This regulatory clearance marks Humanwell Healthcare’s entry into this significant market segment, with the company planning to arrange for production and launch based on market demand.

Additionally, Humanwell Healthcare Group formalized a financial services agreement with China Merchants Group Finance Co., Ltd., previously approved at its September 12, 2025 extraordinary general meeting. The agreement, valid for three years, covers deposit, settlement, credit, foreign exchange, and other financial services, with a daily deposit limit of 2 billion yuan and a daily outstanding loan limit of 5 billion yuan.